2021 IPO

Better Therapeutics Stock

Better develops prescription software for treating cardiometabolic diseases.

Sign up today and learn more about Better Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Better Therapeutics Stock

Better Therapeutics discovers, develops and commercializes prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases. We use clinically-validated, FDA-regulated software to change the behaviors that cause these diseases thereby improving quality of life, reducing the need for medications, and lowering costs. Our products deliver digital behavioral therapy that integrates neuroscience, lifestyle medicine, and explainable AI into a physician-prescribed mobile medical app, and uses patient-generated data to inform clinical decision-making and improve treatment outcomes. Our current product pipeline includes therapeutic candidates for the treatment of type 2 diabetes, hypertension, and dyslipidemia. Our founding team has started, led and exited multiple technology companies that have transformed industries and generated billions of dollars in enterprise value. The 17th Surgeon General of the US, Dr. Richard Carmona, serves as an independent board director. We were founded in 2015 and are headquartered in San Francisco, CA.

Funding History

May 2015$2.0M
December 2015$21.8M

Management

Operations Lead

Lauren Burns

Care Ambassador

Kate Edwards, FNPC, MSN, RN

Co-Founder & CEO

Kevin Appelbaum

Head of Clinical Operations

Richard Morse

Contributing Editor / Interim Health Coach

Georgi Maule-Ffinch

Chief Medical Officer

Dr. Mark Berman

Chief Product Officer

Kristin Wynholds

Advisory Board Member / Senior Medical Advisor

Dr. David Eisenberg

Head of Engineering

Andres Camacho

Senior Health Coach

Laura Matteliano

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo